Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Cash (2016 - 2025)

Historic Change in Cash for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $29.1 million.

  • Akebia Therapeutics' Change in Cash rose 63235.29% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.4 million, marking a year-over-year increase of 116092.6%. This contributed to the annual value of $9.0 million for FY2024, which is 11846.26% up from last year.
  • Akebia Therapeutics' Change in Cash amounted to $29.1 million in Q3 2025, which was up 63235.29% from $23.9 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Change in Cash high stood at $61.5 million for Q1 2025, and its period low was -$57.4 million during Q4 2021.
  • In the last 5 years, Akebia Therapeutics' Change in Cash had a median value of -$3.6 million in 2023 and averaged -$3.3 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Change in Cash plummeted by 91993.09% in 2023, and later surged by 652727.27% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Change in Cash stood at -$57.4 million in 2021, then increased by 4.75% to -$54.7 million in 2022, then skyrocketed by 93.42% to -$3.6 million in 2023, then surged by 596.3% to $17.9 million in 2024, then soared by 63.19% to $29.1 million in 2025.
  • Its Change in Cash was $29.1 million in Q3 2025, compared to $23.9 million in Q2 2025 and $61.5 million in Q1 2025.